Trial results show promising findings for a single injection gene therapy in nAMD patients, reducing need for frequent treatments.
- Trial results of ixoberogene soroparvovec gene therapy for nAMD show a 90-95% reduction in anti-VEGF injections at 26 weeks
- The therapy maintained vision and CST while minimizing inflammation with corticosteroid prophylactic regimens
- Ixo-vec delivers aflibercept continuously in the eye using a modified virus, showing promising results in phase 1 and phase 2 trials
- The ongoing phase 2 LUNA study aims to evaluate lower viral doses and optimal steroid regimens for managing inflammation
- Early insights from the LUNA study show reduced need for anti-VEGF injections, maintenance of visual acuity and CST, and effective inflammation management with mild adverse events.
Source link
Ophthalmology, Oncology, Pharmacists, Nursing